Predictive value of 18F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study

Federico Caobelli, Pierpaolo Alongi, Laura Evangelista, Maria Picchio, Giorgio Saladini, Marco Rensi, Onelio Geatti, Angelo Castello, Iashar Laghai, Cristina E. Popescu, Carlotta Dolci, Cinzia Crivellaro, Silvia Seghezzi, Margarita Kirienko, Vincenzo De Biasi, Fabrizio Cocciolillo, Natale Quartuccio, AIMN Working Group Young AIMN Working Group

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Ovarian cancer is the eighth most common malignancy among women and has a high mortality rate. Prognostic factors able to drive an effective therapy are essential. 18F-Fluoro-2-deoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) has been investigated in patients with epithelial ovarian cancer and showed promise in diagnosing, staging, detecting recurrent lesions and monitoring treatment response. Conversely, its prognostic role remains unclear. We aimed at assessing the prognostic value of 18F-FDG PET/CT performed in the restaging process in a multicentre study. Methods: We evaluated 168 patients affected by ovarian carcinoma, who underwent a restaging 18F-FDG PET/CT. The presence of local recurrences, lymph node involvement and distant metastasis was recorded as well as lesion dimensions, maximum and mean standardized uptake values (SUVmax and SUVmean, respectively). Progression-free survival (PFS) and overall survival (OS) at 3 and 4 years were computed by using Kaplan-Meier curves. Increased odds ratio was assessed using Cox regression analysis testing all lesion parameters measured by PET/CT. Results: PFS was significantly longer in patients with a negative than a positive restaging PET/CT study (3- and 4-year PFS 64 and 53 % vs 23 and 12 %, respectively; p <0.001). Similarly, a negative study was associated with a significantly higher OS rate after 4 years of follow-up (67 vs 25 % in negative and positive groups, respectively; p <0.001). Lymph node or distant involvement were also independently associated with an increased risk of disease progression [hazard ratio (HR) 1.6 and 2.2, respectively; p = 0.003]. Moreover, PET/CT showed an incremental prognostic value compared to the International Federation of Gynecology and Obstetrics (FIGO) staging system. In the analysis of patient subsets, individuals with the same FIGO stage I–II but with negative PET had a significantly better 4-year OS than patients with low FIGO stage but positive PET. This implies that patients with the same FIGO stage can be further prognostically stratified using PET (p = 0.01). At receiver-operating characteristic (ROC) analysis, no thresholds for semiquantitative parameters were predictive of a worse outcome. Conclusion: 18F-FDG PET/CT has an important prognostic value in assessing the risk of disease progression and mortality rate. An efficacious therapy planning might therefore effectively rely on 18F-FDG PET/CT findings. Semiquantitative data were not proven to be an effective tool to predict disease progression.

Original languageEnglish
Pages (from-to)404-413
Number of pages10
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume43
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Keywords

  • F-FDG PET/CT
  • FIGO staging system
  • Ovarian carcinoma
  • Prognostic value
  • Restaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Predictive value of <sup>18</sup>F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study'. Together they form a unique fingerprint.

Cite this